On the Leading Edge of Cancer Research

From its inception, Roswell Park Cancer Institute identified cancer research as the core element of its mission. Since then, groundbreaking research by RPCI scientists has led to greater understanding of the nature of cancer and to major advances in cancer diagnosis and treatment that are now in use worldwide.

RPCI instituted the nation's first chemotherapy program, pioneered studies on the relationship between smoking and lung cancer and developed photodynamic therapy (PDT) and the prostate-specific antigen (PSA) blood test. A comprehensive cancer genetics program, now under development at RPCI, will rival the world's leading programs in that field. The Institute also made significant contributions to the landmark human genome project. RPCI's Center for Pharmacology and Therapeutics is one of the few centers in the nation capable of all phases of drug development, from the conceptual stage through manufacturing and testing. This year RPCI's strong basic and clinical research programs attracted major research grants and contracts totaling more than $81 million. The Institute has sponsored or collaborated on more than 350 clinical trials of promising new cancer treatments.

Drawing more distinguished scientists and clinicians into the fold has enriched RPCI's intellectual base, infusing the atmosphere with new ideas and strategies. The addition of over more than 100 new faculty in less than three years has contributed to a surge in clinical and translational research, propelling RPCI into the highest ranks of leadership in cancer care and innovation.